Annette Lam

1.6k total citations
82 papers, 991 citations indexed

About

Annette Lam is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Annette Lam has authored 82 papers receiving a total of 991 indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Hematology, 27 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Annette Lam's work include Multiple Myeloma Research and Treatments (53 papers), Protein Degradation and Inhibitors (16 papers) and Cancer Treatment and Pharmacology (13 papers). Annette Lam is often cited by papers focused on Multiple Myeloma Research and Treatments (53 papers), Protein Degradation and Inhibitors (16 papers) and Cancer Treatment and Pharmacology (13 papers). Annette Lam collaborates with scholars based in United States, Belgium and France. Annette Lam's co-authors include Jianming He, Saad Z. Usmani, Maneesha Mehra, Ravi Potluri, Meletios Α. Dimopoulos, Joris Diels, Sarah Côté, Jon Ukropec, Mahmoud Hashim and Bart Heeg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Annette Lam

78 papers receiving 965 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annette Lam United States	16	612	486	397	160	75	82	991
L.S. Miller United States	11	565 0.9×	304 0.6×	288 0.7×	219 1.4×	87 1.2×	14	1.2k
Alissa Huston United States	16	274 0.4×	297 0.6×	326 0.8×	33 0.2×	168 2.2×	47	1.0k
Maneesha Mehra United States	14	286 0.5×	239 0.5×	348 0.9×	64 0.4×	76 1.0×	37	985
Deirdre R. Pachman United States	18	209 0.3×	95 0.2×	951 2.4×	36 0.2×	51 0.7×	49	1.3k
Delilah Zabaneh United Kingdom	14	158 0.3×	282 0.6×	75 0.2×	54 0.3×	133 1.8×	20	1.4k
Elizabeth A. McGuire United States	12	275 0.4×	434 0.9×	159 0.4×	36 0.2×	86 1.1×	18	1.1k
Brittany Irvine Canada	8	189 0.3×	175 0.4×	88 0.2×	86 0.5×	74 1.0×	12	693
Isabelle Hubeek Netherlands	11	138 0.2×	285 0.6×	179 0.5×	220 1.4×	52 0.7×	29	934
M. Kurz Austria	9	198 0.3×	116 0.2×	54 0.1×	172 1.1×	41 0.5×	18	557
Sara Tinsley United States	12	308 0.5×	95 0.2×	122 0.3×	26 0.2×	187 2.5×	51	497

Countries citing papers authored by Annette Lam

Since Specialization

Citations

This map shows the geographic impact of Annette Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annette Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annette Lam more than expected).

Fields of papers citing papers by Annette Lam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annette Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annette Lam. The network helps show where Annette Lam may publish in the future.

Co-authorship network of co-authors of Annette Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Annette Lam. A scholar is included among the top collaborators of Annette Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annette Lam. Annette Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dimopoulos, Meletios Α., Pieter Sonneveld, Salomon Manier, et al.. (2024). Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. BMC Cancer. 24(1). 541–541. 1 indexed citations

Durie, Brian G.M., Shaji Kumar, Eric M. Ammann, et al.. (2024). Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data. Advances in Therapy. 41(5). 1923–1937. 2 indexed citations

Rajkumar, S. Vincent, María‐Victoria Mateos, Xiwu Lin, et al.. (2024). Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database. Blood Cancer Journal. 14(1). 215–215.

Tervonen, Tommi, Annette Lam, Katharine S. Gries, et al.. (2023). Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma. Value in Health. 26(6). 909–917. 6 indexed citations

Façon, Thierry, Jesús F. San Miguel, Meletios Α. Dimopoulos, et al.. (2022). Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy. 39(5). 1976–1992. 18 indexed citations

He, Jianming, Bart Heeg, Tobias Kampfenkel, et al.. (2022). Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. Advances in Therapy. 39(9). 4230–4249. 1 indexed citations

Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2021). First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios. Blood. 138(Supplement 1). 118–118. 6 indexed citations

Toro‐Díaz, Hector, et al.. (2020). PCN82 Budget Impact Analysis of Subcutaneous Daratumumab for the Treatment of Patients with Multiple Myeloma in Sweden. Value in Health. 23. S436–S436. 2 indexed citations

Hungria, Vânia, Déborah Martı́nez-Baños, María‐Victoria Mateos, et al.. (2020). Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. Advances in Therapy. 37(12). 4996–5009. 5 indexed citations

10.

Cavo, Michèle, Meletios Α. Dimopoulos, Jesús F. San Miguel, et al.. (2020). Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Clinical Lymphoma Myeloma & Leukemia. 20(7). 480–489. 6 indexed citations

11.

Fonseca, Rafaël, Saad Z. Usmani, Maneesha Mehra, et al.. (2020). Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 20(1). 1087–1087. 67 indexed citations

12.

Dimopoulos, Meletios Α., Jonathan L. Kaufman, Darrell White, et al.. (2018). A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clinical Lymphoma Myeloma & Leukemia. 18(3). 163–173.e6. 18 indexed citations

13.

Hashim, Mahmoud, et al.. (2018). Is There A Consensus Regarding Clinically Relevant Non-Inferiority Margins Used For Key Oncology Endpoints In Non-Inferiority Oncology Trials?. Value in Health. 21. S228–S228. 4 indexed citations

14.

Miguel, Jesús F. San, Thierry Façon, Meletios Α. Dimopoulos, et al.. (2018). PSY17 - TREATMENT REGIMENS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS. Value in Health. 21. S438–S438. 1 indexed citations

15.

Kumar, Shaji, Brian G.M. Durie, Hareth Nahi, et al.. (2018). Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia & lymphoma. 60(1). 163–171. 5 indexed citations

16.

Dimopoulos, Meletios Α., Pieter Sonneveld, Hareth Nahi, et al.. (2017). Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. Value in Health. 20(9). A408–A408. 8 indexed citations

17.

Diels, Joris, Annette Lam, Tetsuro Ito, et al.. (2016). Indirect Comparison Of Daratumumab Monotherapy Versus Real-World Historical Control Data In Patients With Multiple Myeloma Who Are Heavily Pre-Treated And Highly Refractory. Value in Health. 19(3). A140–A140.

18.

Olivares, J.M., Joris Diels, Michael Povey, et al.. (2009). Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). European Psychiatry. 24(5). 287–296. 122 indexed citations

19.

Kohli, Michele, Cheryl Attard, Annette Lam, et al.. (2006). Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada. PharmacoEconomics. 24(8). 815–830. 18 indexed citations

20.

Salapatek, Anne Marie, Yufang Wang, Yukang Mao, Annette Lam, & Edwin E. Daniel. (1998). Myogenic nitric oxide synthase activity in canine lower oesophageal sphincter: morphological and functional evidence. British Journal of Pharmacology. 123(6). 1055–1064. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact